Literature DB >> 11175262

Regulation of Bcl-2-family proteins in myeloma cells by three myeloma survival factors: interleukin-6, interferon-alpha and insulin-like growth factor 1.

M Jourdan1, J De Vos, N Mechti, B Klein.   

Abstract

As survival regulation is a key process in multiple myeloma biology, we have studied the Bcl-2 family proteins that can be regulated by three myeloma cell survival factors: interleukin-6 (IL-6), interferon-alpha (IFN-alpha) and insulin-like growth factor (IGF-1). Eleven myeloma cell lines, whose survival and proliferation are dependent on addition of IL-6, variably expressed 10 anti-apoptotic or pro-apoptotic proteins of the Bcl-2-family. When myeloma cells from four cell lines were IL-6 starved and activated with IL-6 or IFN-alpha, we observed that only Mcl-1 expression was up-regulated with myeloma cell survival induction. Nor was obvious regulation of these 10 pro-apoptotic or anti-apoptotic proteins found with IGF-1, another potent myeloma cell survival factor. Our results indicate that the myeloma cell survival activity of IL-6 linked to Bcl-xL regulation cannot be generalized and emphasize that Mcl-1 is the main target of IL-6 and IFN-alpha stimulation. However, other changes in the activity of the Bcl-2 protein family or other apoptosis regulators must be identified to elucidate the IGF-1 action mechanism. Cell Death and Differentiation (2000) 7, 1244 - 1252.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11175262      PMCID: PMC2423422          DOI: 10.1038/sj.cdd.4400758

Source DB:  PubMed          Journal:  Cell Death Differ        ISSN: 1350-9047            Impact factor:   15.828


  41 in total

1.  Agonist anti-gp130 transducer monoclonal antibodies are human myeloma cell survival and growth factors.

Authors:  Z J Gu; J De Vos; C Rebouissou; M Jourdan; X G Zhang; J F Rossi; J Wijdenes; B Klein
Journal:  Leukemia       Date:  2000-01       Impact factor: 11.528

2.  Mcl-1 and Bcl-xL are co-regulated by IL-6 in human myeloma cells.

Authors:  D Puthier; S Derenne; S Barillé; P Moreau; J L Harousseau; R Bataille; M Amiot
Journal:  Br J Haematol       Date:  1999-11       Impact factor: 6.998

3.  JAK2 tyrosine kinase inhibitor tyrphostin AG490 downregulates the mitogen-activated protein kinase (MAPK) and signal transducer and activator of transcription (STAT) pathways and induces apoptosis in myeloma cells.

Authors:  J De Vos; M Jourdan; K Tarte; C Jasmin; B Klein
Journal:  Br J Haematol       Date:  2000-06       Impact factor: 6.998

4.  Insulin-like growth factor induces the survival and proliferation of myeloma cells through an interleukin-6-independent transduction pathway.

Authors:  M Ferlin; N Noraz; C Hertogh; J Brochier; N Taylor; B Klein
Journal:  Br J Haematol       Date:  2000-11       Impact factor: 6.998

5.  IL-6 up-regulates mcl-1 in human myeloma cells through JAK / STAT rather than ras / MAP kinase pathway.

Authors:  D Puthier; R Bataille; M Amiot
Journal:  Eur J Immunol       Date:  1999-12       Impact factor: 5.532

6.  Normal and neoplastic human plasma cells express bcl-2 antigen.

Authors:  M S Hamilton; H F Barker; J Ball; M Drew; S D Abbot; I M Franklin
Journal:  Leukemia       Date:  1991-09       Impact factor: 11.528

7.  Expression of the bcl-2 gene in human multiple myeloma cell lines and normal plasma cells.

Authors:  M Pettersson; H Jernberg-Wiklund; L G Larsson; C Sundström; I Givol; Y Tsujimoto; K Nilsson
Journal:  Blood       Date:  1992-01-15       Impact factor: 22.113

8.  Value of beta 2-microglobulin level and plasma cell labeling indices as prognostic factors in patients with newly diagnosed myeloma.

Authors:  P R Greipp; J A Katzmann; W M O'Fallon; R A Kyle
Journal:  Blood       Date:  1988-07       Impact factor: 22.113

9.  Growth kinetics of plasma cell myeloma.

Authors:  B Drewinko; R Alexanian
Journal:  J Natl Cancer Inst       Date:  1977-05       Impact factor: 13.506

10.  Ciliary neurotropic factor, interleukin 11, leukemia inhibitory factor, and oncostatin M are growth factors for human myeloma cell lines using the interleukin 6 signal transducer gp130.

Authors:  X G Zhang; J J Gu; Z Y Lu; K Yasukawa; G D Yancopoulos; K Turner; M Shoyab; T Taga; T Kishimoto; R Bataille
Journal:  J Exp Med       Date:  1994-04-01       Impact factor: 14.307

View more
  48 in total

1.  IL-6/STAT3 signaling pathway is activated in plasma cell mastitis.

Authors:  Yang Liu; Jian Zhang; Yu-Hui Zhou; Yi-Na Jiang; Wei Zhang; Xiao-Jiang Tang; Yu Ren; Shui-Ping Han; Pei-Jun Liu; Jing Xu; Jian-Jun He
Journal:  Int J Clin Exp Pathol       Date:  2015-10-01

Review 2.  Role of Histone Deacetylase Inhibitors in Relapsed Refractory Multiple Myeloma: A Focus on Vorinostat and Panobinostat.

Authors:  Salma Afifi; Angela Michael; Mahshid Azimi; Mabel Rodriguez; Nikoletta Lendvai; Ola Landgren
Journal:  Pharmacotherapy       Date:  2015-12       Impact factor: 4.705

3.  CpG DNA activation and plasma-cell differentiation of CD27- naive human B cells.

Authors:  Jennifer Huggins; Tina Pellegrin; Raymond E Felgar; Chungwen Wei; Miguel Brown; Bo Zheng; Eric C B Milner; Steven H Bernstein; Ignacio Sanz; Martin S Zand
Journal:  Blood       Date:  2006-10-10       Impact factor: 22.113

4.  Gene expression of anti- and pro-apoptotic proteins in malignant and normal plasma cells.

Authors:  Michel Jourdan; Thierry Reme; Hartmut Goldschmidt; Geneviève Fiol; Véronique Pantesco; John De Vos; Jean-François Rossi; Dirk Hose; Bernard Klein
Journal:  Br J Haematol       Date:  2009-01-08       Impact factor: 6.998

Review 5.  Sphingosine 1-phosphate signaling impacts lymphocyte migration, inflammation and infection.

Authors:  Irina V Tiper; James E East; Priyanka B Subrahmanyam; Tonya J Webb
Journal:  Pathog Dis       Date:  2016-06-27       Impact factor: 3.166

6.  Bone marrow microenvironment-derived signals induce Mcl-1 dependence in multiple myeloma.

Authors:  Vikas A Gupta; Shannon M Matulis; Jason E Conage-Pough; Ajay K Nooka; Jonathan L Kaufman; Sagar Lonial; Lawrence H Boise
Journal:  Blood       Date:  2017-02-01       Impact factor: 22.113

7.  The Bcl-2 family member Bfl-1/A1 is strongly repressed in normal and malignant plasma cells but is a potent anti-apoptotic factor for myeloma cells.

Authors:  Karin Tarte; Michel Jourdan; Jean Luc Veyrune; Ingolf Berberich; Geneviève Fiol; Nicole Redal; John Shaughnessy; Bernard Klein
Journal:  Br J Haematol       Date:  2004-05       Impact factor: 6.998

8.  G1P3, an IFN-induced survival factor, antagonizes TRAIL-induced apoptosis in human myeloma cells.

Authors:  Venugopalan Cheriyath; Keith B Glaser; Jeffrey F Waring; Rachid Baz; Mohamad A Hussein; Ernest C Borden
Journal:  J Clin Invest       Date:  2007-10       Impact factor: 14.808

9.  BAFF and APRIL protect myeloma cells from apoptosis induced by interleukin 6 deprivation and dexamethasone.

Authors:  Jérôme Moreaux; Eric Legouffe; Eric Jourdan; Philippe Quittet; Thierry Rème; Cécile Lugagne; Philippe Moine; Jean-François Rossi; Bernard Klein; Karin Tarte
Journal:  Blood       Date:  2003-12-04       Impact factor: 22.113

10.  Growth factors in multiple myeloma: a comprehensive analysis of their expression in tumor cells and bone marrow environment using Affymetrix microarrays.

Authors:  Karène Mahtouk; Jérôme Moreaux; Dirk Hose; Thierry Rème; Tobias Meissner; Michel Jourdan; Jean François Rossi; Steven T Pals; Hartmut Goldschmidt; Bernard Klein
Journal:  BMC Cancer       Date:  2010-05-13       Impact factor: 4.430

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.